Figure 4. Signaling connected with the PI3K/Akt/mTOR pathway and altered in SI-NETs.

Cancer therapeutics target multiple proteins in connected signaling cascades. Candidate therapeutically actionable genome alterations were noted in 72% of SI-NET patients. FLT3, fms-like tyrosine kinase receptor 3.